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Antimicrobial peptides (AMPs) are promising next generation antibiotics that hold great
potential for combating bacterial resistance. AMPs can be both bacteriostatic and
bactericidal, induce rapid killing and display a lower propensity to develop resistance than
do conventional antibiotics. Despite significant progress in the past 30 years, no peptide
antibiotic has reached the clinic yet. Poor understanding of the action mechanisms and
lack of rational design principles have been the two major obstacles that have slowed
progress. Technological developments are now enabling multidisciplinary approaches
including molecular dynamics simulations combined with biophysics and microbiology
toward providing valuable insights into the interactions of AMPs with membranes at
atomic level. This has led to increasingly robust models of the mechanisms of action
of AMPs and has begun to contribute meaningfully toward the discovery of new AMPs.
This review discusses the detailed action mechanisms that have been put forward, with
detailed atomistic insights into how the AMPs interact with bacterial membranes. The
review further discusses how this knowledge is exploited toward developing design
principles for novel AMPs. Finally, the current status, associated challenges, and future
directions for the development of AMP therapeutics are discussed.
Keywords: antimicrobial peptides, action mechanism, membrane, antibiotic resistance, peptide antibiotics
INTRODUCTION
The continued emergence of resistant pathogens world-wide, particularly among Gram-negative
bacteria, has become a leading health care challenge (McKenna, 2013). Resistant strains of
bacteria/fungus/yeast are regularly being found for almost every antimicrobial used clinically.
On the other hand, a decline in the approval of new antibiotics has further exacerbated the
problem, leading to an “antibiotic crisis” (Livermore, 2004). Persistence of the current situation
is driving clinicians to use drugs that are associated with significant toxicity. In contrast to small
molecule antibiotics, antimicrobial peptides (AMPs) act on the bacterial membrane which is
Abbreviations: AMP, Antimicrobial peptide; POPE, Phosphatidylethanolamine; POPG, Phosphatidylglycerol; POPC,
Phosphatidylcholine; POPS, Phosphatidylserine; CL, Cardiolipin; LPS, Lipopolysaccharide; SAR, Structure-activity
relationship; CD, Circular dichroism; MD, Molecular dynamics; MRSA, methicillin-resistant Staphylococcus aureus; MIC,
minimum inhibitory concentration.
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an evolutionarily conserved component of bacterial cells
(Yeaman and Yount, 2003). Bacterial membranes define the
phenotype and membrane mutations would likely be costly
for bacteria, therefore AMPs are less likely to induce bacterial
resistance (Zasloff, 2002). Moreover, AMPs are bactericidal
and they kill bacteria much more rapidly than conventional
antibiotics (Zasloff, 1987; Romeo et al., 1988; Mygind et al., 2005;
Marr et al., 2006; Bai et al., 2012; Deslouches et al., 2013).
There are more than 2,000 naturally occurring and synthetic
AMPs (Wang G. et al., 2016). Naturally occurring AMPs,
including defensins, are produced in various living organisms
including humans and are part of the innate immune system
(Diamond et al., 2009). In humans, these molecules are found
in lymphocytes and epithelial surfaces (e.g., skin, eye, lung,
and intestines etc.). For example, Paneth cells, the specialized
secretory epithelial cells in the small intestine, produce high levels
of AMPs (e.g., alpha-defensins, lysozyme etc.), resulting in a
controlled number of bacteria in the small intestine (Ayabe et al.,
2004; Bevins and Salzman, 2011). The tear fluid of the eye is also
a rich source of AMPs and include the defensins, lysozyme, and
cathelicidins, protecting the eyes from infections (McDermott,
2013). Other AMPs can be either synthesized ribosomally
or produced non-ribosomally in bacteria and fungi during
cultivation on various carbon sources (Makovitzki et al., 2006).
Lipopeptides such as polymyxins are produced as metabolites in
bacteria or fungi. However, these are also membrane targeting,
so, in this review, the general term, AMP will be used to refer
to them. In addition to their antimicrobial-activity, some AMPs
have other important roles in immune regulation, inflammation,
anti-cancer, sepsis, and wound healing. Indeed, some AMPs
demonstrate not only antimicrobial, but also anti-inflammatory
and immune regulatory activities (Sjogren, 2004; Gordon et al.,
2005). The non-antimicrobial functions of AMPs are out of
the scope of this review, and the interested reader can refer to
relevant references (Ganz, 2003a,b; Marta Guarna et al., 2006;
Van Lenten et al., 2008; McCormick and Weinberg, 2010; Shin
and Jo, 2011; Li et al., 2012; Schuerholz et al., 2012; Gaspar et al.,
2013; Hilchie et al., 2013; Martin et al., 2015a,b; Brandenburg
et al., 2016).
AMPs are generally short peptides with <50 amino acids.
Although there are more than 2,000 naturally occurring or
synthetic AMPs, their lengths, sequences and 3-dimensional
(3-D) conformations differ significantly, making it difficult
to relate the sequence/structure to antimicrobial activity.
Moreover, AMPs can undergo conformational changes upon
adsorption onto the bacterial membrane and have evolved
several mechanisms of action, which further complicate the
analysis of a structure-activity relationship (SAR). As there
is insufficient detailed knowledge of the action mechanisms
in bacteria, synthetic AMPs are generally designed by trial
and error (Epand and Vogel, 1999). Overcoming this gap in
understanding could make antibiotic design closer to what is
the common structure based approach for drug design and
the action mechanism is crucial to this goal. Although the
action mechanism for AMPs have been discussed in earlier
reviews, most of them focus on the description of the general
features of empirical models (e.g., pore-forming and carpet
models), few discuss the detailed atomistic events and the
dynamic processes of AMP mechanisms of action (Epand and
Vogel, 1999; Shai, 2002; Guilhelmelli et al., 2013; Lee et al.,
2016). Recently, the employment of molecular dynamics (MD)
simulations has deepened our understanding of the underlying
action mechanism at a molecular level. Based on insights at
atomic level, rational molecular principles have been put forward
for the development of AMP therapeutics. Our primary focus
in this review is to provide a fundamental understanding
of the atomistic mechanisms of various AMPs and discuss
molecular principles for practical AMP design. In addition,
the current status of development of AMP antibiotics as well
as challenges and future prospects for AMP therapeutics are
discussed.
MODES OF ACTION OF AMPS
Structure of the Bacterial Membrane: The
Target of AMPs
To understand the mode of action of AMPs, we begin with a
discussion of the structure and physical properties of the bacterial
membrane-the target of AMPs. Bacteria are broadly classified
as either Gram-positive or Gram-negative, characterized by
significant differences in their cell envelopes (Figure 1). The
inner or cytoplasmic membranes of both bacteria groups are
similar. However, the outer cell envelopes are significantly
different. In Gram-positive bacteria, there is a layer of crosslinked
peptidoglycan decorated with negatively charged teichoic acid
surrounding the cytoplasmic membrane, forming a thick matrix
which maintains the rigidity of the bacterial cell. Nano-sized
pores penetrate into the peptidoglycan layers, allowing AMPs
to diffuse through (Meroueh et al., 2006). In contrast, the
peptidoglycan layer in Gram-negative bacteria is much thinner
and less cross-linked. In addition, Gram-negative bacteria have
an additional outer membrane outside the peptidoglycan layer.
The inner leaflet consists purely of phosphate lipids while the
outer leaflet is primarily a coat of lipopolysaccharide (LPS; Ruiz
et al., 2006). LPS molecules are decorated with a high number
of negatively charged phosphate groups that are engaged in salt-
bridges with divalent cations (e.g., Ca2+ and Mg2+), resulting in
an electrostatic network (Nikaido, 2003). This electrostatic region
serves as a primary barrier to most hydrophobic antibiotics,
resulting in low permeability. Therefore, the details as to how
AMPs penetrate into Gram-positive and Gram-negative bacteria
must vary in their atomistic interactions. In the case of Gram-
positive bacteria, AMPs need to diffuse across the peptidoglycan
matrix first and then act on the cytoplasmic membrane. In
contrast, killing Gram-negative bacteria involves perturbation or
disruption of both outer and cytoplasmic membranes. Inability
to permeabilize or disrupt the outer membrane results in the
loss of antimicrobial activity. Daptomycin is able to disrupt
the cytoplasmic membrane, but not able to permeabilize/disrupt
the outer membrane of Gram-negative bacteria. As such, it is
highly active against Gram-positive bacteria such as methicillin-
resistant Staphylococcus aureus (MRSA), but has no activity
against Gram-negative bacteria (Tally and DeBruin, 2000).
Frontiers in Neuroscience | www.frontiersin.org 2 February 2017 | Volume 11 | Article 73
Li et al. Peptide Antibiotics
FIGURE 1 | Schematic membrane structures of Gram-positive and Gram-negative bacteria. The cytoplasmic membranes of both types of bacteria are
similar. Gram-positive bacteria have a thick layer of peptidoglycan surrounding the cytoplasmic membrane, protecting the bacterium. In contrast, the layer of
peptidoglycan in Gram-negative bacteria is thin and an additional outer membrane is present. LPS forms a major part of the outer leaflet of the outer membrane/cell
wall, the inner leaflet is comprised of phospholipids.
Parameters Affecting AMP Movement to
the Cytoplasmic Membrane
The cytoplasmic membrane (also called as the inner membrane)
of Gram-positive and Gram-negative bacteria are comprised
of a mixture of zwitterionic and anionic phospholipids,
such as phosphatidylethanolamine (POPE), phosphatidylglycerol
(POPG), and cardiolipin (CL). Models of action for AMPs acting
on the cytoplasmic membrane include pore formation (e.g.,
barrel stave or toroidal pores) and carpet mechanism (Brogden,
2005; Melo et al., 2009). For an AMP to disrupt the cytoplasmic
membrane, the AMP molecules must first accumulate on the
membrane surface up to a critical concentration. However,
diffusion barriers in either the outer membrane or the
periplasmic space affect their partition onto the membrane.
This is a more direct path for Gram-positive bacteria as
the AMPs only need to diffuse through nano-sized pores
in the peptidoglycan, which in most cases is not a rate-
limiting step (Vollmer et al., 2008). In fact, the peptidoglycan
layer can facilitate AMP accumulation on the surface of the
cytoplasmic membrane due to favorable interactions between
teichoic acid and cationic AMPs (Malanovic and Lohner,
2016).
In the case of Gram-negative pathogens, AMPs need
to permeabilize or disrupt both the outer and cytoplasmic
membranes, resulting in a two-step process (Figure 2;
Schwechheimer and Kuehn, 2015). Although the outer
membrane of Gram-negative pathogens significantly modulates
the antimicrobial activity of AMPs, in most cases, the inner
membrane is the rate-limiting step. For example, polymyxin
B has strong antimicrobial activity against Gram-negative
pathogens due to its ability to disrupt both the outer and the
cytoplasmic membranes. However, removing the lipid tail
resulting in polymyxin B nonapeptide, and only the outer
membrane is permeabilized. As a result, the nonapeptide also
loses antimicrobial activity (Ofek et al., 1994).
The detailed mode of interactions between AMPs and the
outer membrane of Gram-negative bacteria is poorly understood
due to the complex structure of the LPSmolecules, which consists
of a lipid A component, an inner and an outer core portion and
a sugar portion (Figure 2). The initial event is the adsorption
onto the outer membrane surface, which can occur within
tens of nanoseconds and is largely mediated by electrostatic
interactions between cationic AMPs and anionic LPS molecules.
Reduction in the electrostatic driving force significantly affects
the partition of AMPs to the outer membrane and may result in
the loss of antimicrobial activity. For example, modification of
the phosphate groups on the LPS molecules such as deacylation,
hydroxylation, or addition of phosphoethanolamine endows
bacteria resistance to colistin (polymyxin E; Olaitan et al.,
2014). Upon adsorption onto the outer membrane, AMPs form
hydrogen bonds with the phosphate groups, disrupting the salt-
bridges between phosphate groups and divalent cations and
destabilizing the outer membrane. In addition to the electrostatic
forces, the hydrophobic moieties of an AMP can also interact
with the lipid tails of the LPS molecule, further destabilizing
the close packing of the outer membrane. After the AMP
permeabilizes/disrupts the outer membrane, it diffuses inward
to the periplasmic space and adsorbs onto the surface of the
cytoplasmic membrane. Once a critical surface concentration
on the cytoplasmic membrane is reached, the AMP induces
significant perturbations and disorganizations of the cytoplasmic
membrane, resulting in loss of the transmembrane potential, and
eventual death of the bacterial cell.
Characteristics of the interactions of AMP with the outer and
cytoplasmic membranes include: length of the AMP sequence,
the total and density of cationic charges, the total number
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FIGURE 2 | Key molecular events of the interaction of an AMP which results in killing Gram-negative baceria. Step 1, adsorption of the AMP to the surface
of the outer membrane, which is very rapid (t = ns, nanosec) and is driven by electrostatic interactions. Step 2, permeabilization of the outer membrane, which is
mediated by complex interactions including electrostatic interactions, hydrogen bonds, and hydrophobic interactions. In step 3, the AMP diffuses through the
periplasmic space and reaches the surface of the inner membrane. Step 4 is the disruption of the cytoplasmic membrane, loss of the transmembrane potential, influx
of water, and killing of the bacteria.
of hydrogen bonds donors and the 3-D conformation of the
AMP in solution and at the membrane (Sitaram and Nagaraj,
1999; Bürck et al., 2008). The AMP structures that have been
determined experimentally and deposited into the protein data
bank provide little information for SAR as these structures are
either in solution or in crystals rather than in the membrane
environment. Due to the short sequences of most AMPs, their
structures are sensitive to their environment. By comparing
the CD spectrum of AMPs in solution and in the presence of
liposomes, a large number of AMPs (e.g., melittin, magainin)
have been found to undergo conformational transitions from
random conformations in solution to helical or beta-sheet
conformations on the membrane surface (Ramamoorthy et al.,
2006; Hartings et al., 2008). For example, melittin adopts a helical
conformation and protegrin adopts a beta-sheet conformation
upon adsorption onto the membrane surface (Blazyk et al.,
2001; Lu et al., 2005; Rausch et al., 2005, 2007; Dong et al.,
2012). In silico modeling further reveals that both the alpha-
helical and beta-sheet conformations are amphiphilic, with the
cationic residues interacting with the anionic head groups and
the hydrophobic residues penetrating into the lipid tail region
of the membrane. Hence the electrostatic and hydrophobic
interactions are two driving forces that steer an AMP toward and
into the bacterial membrane.
Early Events in AMP Disruption of the
Cytoplasmic Membrane
After adsorption onto the membrane surface, AMPs can induce
a variety of membrane perturbations within tens of nanoseconds
(Li et al., 2013). For most AMPs, an early event is the formation
of hydrogen bonds between the basic residues (e.g., arginine and
lysine) and the phosphate groups of the lipids. At physiological
conditions, both lysine and arginine are hydrogen bond donors.
However, arginine can form more stable bidentate hydrogen
bonds with phosphate groups. Hydrophobic residues can further
penetrate and disorganize the lipid tail region of the membrane.
As more AMP molecules accumulate at the membrane-water
interface, the membrane becomes thin, as observed for most
AMPs (Sato and Feix, 2006; Ye et al., 2010). Moreover, as the
total volume of the membrane is roughly constant, membrane
thinning results in lateral expansion, affecting the mechanical
properties of the membrane. For example, with the increase
in the area per lipid, the surface tension increases and the
bending modulus decreases dramatically, implying membrane
deformation (Szleifer et al., 1988; Stevens, 2004). The expansion
of the membrane also results in reduction in the packing of
the lipid molecules leading to the formation of a large number
of cavities, significantly reducing the translocation free energy
of water molecules across the lipid tail region. As a result, a
large number of water translocations occur, and the membrane
becomes leaky with the collapse of the transmembrane potential
and additional membrane dysfunction, such as inhibition of ATP
production and loss of proton motive force (Dimroth et al., 2000)
and rapid death of the bacterium.
Some AMPs, particularly the highly cationic ones can induce
lipid re-arrangements and the formation of lipid rafts. B2088, an
18 residue peptide dimer with a high content of basic residues
(12 positive charges), once adsorbed on the bacterial membrane,
was found to recruit anionic lipids surrounding the peptide,
resulting in micro-domains rich in anionic lipids in the outer
leaflet of the membrane (Bai et al., 2012). Due to the binding to
AMPs, lipid molecules surrounding AMPmolecules display slow
diffusivity, which not only affects the fluidity and structure of
the membrane, but also results in significant tension, particularly
along the domain boundaries (Guo et al., 2011). Clustering of
anionic lipids in model bacterial membranes was found for other
peptides as well (Oreopoulos et al., 2010; Polyansky et al., 2010;
Wadhwani et al., 2012; Scheinpflug et al., 2015). SomeAMPswere
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found to even induce flip-flop of anionic lipids from the inner
leaflet to the outer leaflet, resulting in highly negatively charged
outer leaflet and less negatively charged inner leaflet (Qian and
Heller, 2011). This asymmetric distribution of charged lipids
further destroys the membrane potential, resulting in membrane
destabilization.
Membrane geometry as measured by the curvature is a
fundamental property denoting stability with its basis in lipid
organization and protein inclusions. Wong and coworkers
suggested that negative Gaussian curvature is a prerequisite
topology for the formation of membrane pores (Schmidt et al.,
2010, 2011; Schmidt and Wong, 2013). It was found that POPE
has the highest tendency to form a negative Gaussian curvature
(“saddle-splay”) because of its small head group with respect
to its large lipid tails (Yang et al., 2007; Schmidt et al., 2011).
Interestingly, bacterial membranes consist of a high percentage
of POPE while human membranes are mainly composed of
POPC, implying that the preference of AMPS for POPE-rich
membranes contributes significantly to the selectivity of AMPs.
MD simulation studies have also shown that arginine residues
can induce higher negative Gaussian curvature than lysine
residues. The guanidinium group of arginine can form bidentate
hydrogen bonds and coordinate two phosphate groups at <0.5
nm, while the distance is 0.7 nm for lysine (Schmidt et al.,
2012a,b; Wu et al., 2013). Wu et al. employed both coarse-
grained and atomistic models to simulate the interactions of
poly-arginine and poly-lysine with model bacterial membranes
(Wu et al., 2013). Their results revealed the different interactions
of arginine and lysine residues with lipid molecules. The
guanidinium group of arginine can simultaneously interact with
both phosphate and glycerol groups, and thus induce greater
negative Gaussian curvatures than lysine residues, as the latter
can only engage interactions with phosphate groups. Wong
and coworkers also found that incorporation of hydrophobic
moieties further reinforces negative Gaussian curvature, which is
consistent with the antimicrobial activity of various arginine-rich
AMPs. For example, a series (RW)n peptides, which consists of
only arginine (R) and tryptophan (W), display high antimicrobial
activity (Strøm et al., 2002, 2003; Chan et al., 2006). In particular,
an analog of (RW)n peptide LTX-109 has entered into clinical
trials (Isaksson et al., 2011b).
Molecular Models of Pore Formation
A number of AMPs form membrane pores (Table 1). The
timescale of pore formation ranges from microseconds to
seconds. Membrane pores result in the loss of membrane
potential and rapid release of intracellular components and
death. Depending on the geometry of the pores as well as the
interactions of AMPs with the pores, pores can be described by
the barrel-stave or the toroidal model (Figure 3). The formation
of barrel-stave pores is driven by hydrophobic match. In this
model, the membrane does not display significant curvature and
the hydration of the membrane remains unchanged. In the case
of the toroidal model, as the AMP molecules penetrate deeper
into the membrane, the head groups of the lipids are dragged
into the lipid tail region to form toroidal shaped pores while
the lipid tails are packed away from the surface of the pore,
resulting in significant lipid disorder, and membrane curvature
TABLE 1 | Representative AMPs and their modes of action.
AMPs Sequence Mechanism References
Maculatin 1.1 GLFVGVLAKVAAHVVPAIAEHF Pore Dye leakage experiment and MD simulations (Chen and Mark, 2011; Sani et al.,
2013)
Caerin 1.1 GLLSVLGSVAKHVLPHVVPVIAEHL Pore MD simulations (Chen and Mark, 2011)
Cateslytin RSMRLSFRARGYGFR Pore MD simulations and Patch-clamp experiment (Jean-François et al., 2008)
Gramicidin A VGALAVVVWLWLWLW Pore NMR (Urry, 1971; Ketchem et al., 1993)
Alamethicin PAAAAQAVAGLAPVAAEQ Barrel stave pore Ion conductance experiment and statistical analysis (Boheim, 1974; Laver, 1994)
Magainin H2 IIKKFLHSIWKFGKAFVGEIMNI Pore Ion conductance experiment and MD simulations (Matsuzaki, 1998; Leontiadou
et al., 2006)
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ Toroidal pore Dye leakage and grazing-Angle X-Ray Anomalous Diffraction and MD simulations
(Yang et al., 2001; Sengupta et al., 2008; Lee et al., 2013; Leveritt et al., 2015)
Protegrin 1 RGGRLCYCRRRFCVCVGR Pore Ion conductance experiment (Sokolov et al., 1999)
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Toroidal pore NMR (Henzler Wildman et al., 2003)
Indolicidin ILPWKWPWWPWRR Pore Ion conductance experiment (Falla et al., 1996)
Pardaxin 1 GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE Barrel stave pore NMR (Porcelli et al., 2004; Ramamoorthy et al., 2010)
MSI peptide GIGKFLHSAKKFGKAFVGEIMNS Carpet NMR (Lee et al., 2015)
Citropin 1.1 GLFDVIKKVASVIGGL Carpet MD simulations (Chen and Mark, 2011)
Aurein 1.2 GLFDIIKKIAESF Carpet Quartz crystal microbalance with dissipation, vesicle dye leakage and atomic
force microscopy experiments and MD simulations (Chen and Mark, 2011;
Fernandez et al., 2012)
B2088 (RGRKVVRR)2KK Carpet MD simulations (Li et al., 2013)
PL-5 Ac-KWKSFLKTFKS-A-AKTVLHTALKAISS-amide In clinical trials. ProteLight-Pharmaceuticalal, 2016a
ahttp://www.protelight.com/english/Content.asp?Action=ArticleShow&Columns=26&Category=27&Articleid=80.
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FIGURE 3 | The membrane systems of Gram-positive and Gram-negative bacteria and the action mechanisms of AMPs on the cytoplasmic
membrane. For Gram negative bacteria, the AMP needs to permeabilize the outer membrane before reach the cytoplasmic membrane, whereas for Gram positive
bacteria, the AMP only needs to diffuse through the peptidoglycan layer via nano-sized pores. After adsorption onto the cytoplasmic membrane, the AMP can induce
membrane pores such as barrel-stave pore and toroidal pore, or defragment the membrane.
change (Sengupta et al., 2008). As a result, toroidal pores are also
accompanied by enhanced membrane hydration, as evidenced
by significant water penetration into the membrane (Sengupta
et al., 2008; Manna and Mukhopadhyay, 2009). In toroidal pores,
AMPs primarily interact with the pores electrostatically since
the surface of toroidal pores are covered by the phosphate head
groups and the AMP molecules have less hydrophobic contact
with the lipid tails. In contrast, in barrel stave pores, both
electrostatic and hydrophobic interactions are important since
the AMP molecules interact with both the head groups and the
lipid tails (Mihajlovic and Lazaridis, 2010; Bertelsen et al., 2012).
Although induction of membrane pores is a general
mechanism for a large number of AMPs, the morphology of
these membrane pores can be quite diverse in terms of pore
diameter, lipid conformation surrounding the pore, life time of
the pore (e.g., transient pore or permanent pore) and the number
of AMP molecules required to stabilize the pore. Regarding
the shape of the pore, AMPs such as alamethicin, dermcidin,
and pardaxin induce barrel stave pores (Laver, 1994; Porcelli
et al., 2004; Song et al., 2013), while most other AMPs induce
toroidal pores (Matsuzaki, 1998; Sokolov et al., 1999; Yang et al.,
2001; Henzler Wildman et al., 2003; Sengupta et al., 2008; Lee
et al., 2013). In terms of the pore size, magainin induces small
toroidal pores of∼ 2–3 nm in diameter that only allow water and
small intracellular molecules to leak out (Takeshima et al., 2003;
Brogden, 2005), while lacticin Q and protegrin can form much
larger pores of 4.6 and 9 nm in diameter, respectively, allowing
the leakage of much large intracellular molecules (Yoneyama
et al., 2009; Lam et al., 2012). In addition, the pore size
depends on various factors such as the lipid composition and
the peptide/lipid ratio. At nanomolar concentrations, melittin
can only induce transient pores. As the melittin concentration
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increases beyond a critical value (e.g., peptide/lipid ratio of 1/45),
it induces stable membrane pores of 2.5–3 nm in diameter,
and the pore size further increases with the peptide/lipid ratio
(Terwilliger et al., 1982; Matsuzaki et al., 1997; Lee et al.,
2013). Another well-studied AMP, maculatin can also form an
ensemble of structurally diverse pores (Wang Y. et al., 2016).
Moreover, the formation ofmembrane pores depends on the lipid
composition of the membrane as well. Evidence for this lies in
the observation that most AMPs induce membrane pores at a
much higher concentration in mammalian membranes than in
bacterial membranes. The former mainly consists of zwitterionic
lipids (e.g., POPC) and cholesterol, which are closely packed and
thus have a low tendency to form membrane pores. In contrast,
bacterial membranes consist of high percentage of POPE, which
has a small head group and thus has higher tendency to form
negative Gaussian curvatures, as discussed above (Schmidt and
Wong, 2013).
Biophysical methods used to study the pore structure as well
as AMP conformations in the pores, include small angle x-ray
scattering (SAXS), oriented circular dichroism (OCD, solid-state
NMR, quartz crystal microbalance (QCM; Yang et al., 2007;
Kwon et al., 2013; Wang et al., 2015; Bürck et al., 2016). However,
these methods typically give the early or final states of the AMP-
membrane complex, e.g., the static structures of AMPs and
membrane pores. The dynamics of the pore formation process
is missing because the intermediate states of pore formation are
either in non-equilibrium or metastable states and thus have
life times that are too short to be observed. To obtain dynamic
information on pore formation, MD simulations using atomistic
and coarse-grained models have been carried out (Edit et al.,
2007; Kirsch and Böckmann, 2016). Due to the complexity of
the pore formation process, the sub-microsecond time scales that
MD simulations can access and the fact that pore formation is a
rare event, it is still difficult to observe the complete process of
pore formation in conventional MD simulations. Nevertheless,
Leontiadou et al. were the first to successfully simulate the process
of toroidal pore formation by magainin (Leontiadou et al., 2006).
In the simulations, the toroidal pore displays higher disorder than
the normal toroidal pore model, reflecting the dynamic nature of
pores inmembranes. In another simulation from the same group,
similar effects were observed for melittin. One or two melittin
molecules were observed to line within the pore axis, while other
peptide molecules located at the two ends of the pore (Sengupta
et al., 2008). Removing the positive charges of melittin molecules
failed to induce membrane pores, revealing the importance
of electrostatic interactions. Interestingly, in both simulations,
peptides lose their helical conformations when binding to the
membrane pores, suggesting that the helical conformation is
not necessary for stabilization of the membrane pores, at least
for the case of toroidal pores. Coarse-grained MD simulations
were also performed for melittin and transient toroidal pores
were observed at high peptide/lipid ratios (Santo et al., 2013).
It was shown that typically 3–5 melittin molecules are involved
in each pore and similar to the atomistic simulations, not all
the melittin molecules span across the membrane. The difference
in the pores between atomistic and coarse-grained simulations
suggests diverse morphologies of melittin induced membrane
pores. These MD simulations, although only carried out at a
micro-second time scale, nevertheless provide valuablemolecular
insights into the action mechanism of AMPs.
Carpet Mechanism
Not all AMPs induce membrane pores. Some AMPs adsorb onto
the membrane surface and orient parallel to the membrane. As
their surface concentrations reach a critical value, these AMPs
disrupt the integrity of the super molecular structure of the
membrane via membrane fragmentation, a process called carpet
mechanism or detergent model (Figure 3; Gazit et al., 1996).
Some examples of AMPs with carpet mechanism are listed in
Table 1. In the carpet model, the outer leaflet is covered by a
high surface concentration of AMP molecules, while the inner
leaflet is free of AMP binding. The large imbalance of charge
and surface tension across the membrane eventually leads to
catastrophic collapse of membrane integrity and leakage of the
cytoplasmic contents, ions, and biomolecules. In contrast, in the
pore forming mechanism, only intracellular molecules smaller
than the pore can exit. The size of the released molecules can be
used to distinguish the pore forming mechanism from a carpet
mechanism.
In the carpet mechanism, the complete picture of membrane
collapse is not well-understood because (i) the process is
highly non-equilibrium; (ii) multiple pathways of membrane
lysis exist, making it difficult to be detected in biophysical
experiments. However, at a peptide concentration lower than the
critical concentration, the membrane undergoes some intrinsic
perturbations such as membrane thinning, lateral expansion,
clustering of anionic lipids, and membrane deformation,
and high surface tension. Interestingly, these membrane
perturbations can be used to correlate to the subsequent
membrane lysis. For example, Wimley proposed an interfacial
activity model to relate these membrane perturbations to the
membrane activity of an AMP (Wimley, 2010). In the surface
activity model, the membrane activity of an AMP is a function
of the surface activity, which depends on two elements: (i) the
partition of an AMP to the surface of the bacterial membrane
and (ii) the ability to induce membrane perturbations. As the
former is mostly driven by electrostatic interactions, AMPs with
greater charge are more likely to achieve high concentrations on
the membrane surface. The latter depends on many factors such
as the 3-D conformation of the AMP, the physical properties
of the AMP, and the actual interactions of the AMP with the
lipids. Given the fact that the membrane is amphiphilic in
nature, AMPs with facial amphiphilicity display high affinity
for the membrane. The destabilization of the hydrophobic-
water interface is critical for subsequent membrane lysis. In
addition, membrane perturbations can be further enhanced via
AMP aggregation, a mechanism similar to the toxic effects of
an amyloid peptide (Milov et al., 2009; Di Scala et al., 2016).
For example, LL-37, HAL-2, and the C-terminal segment of
human beta-defensin 3, can achieve high surface concentration
via self-aggregation upon adsorption onto the surface (Bai
et al., 2009; Wang et al., 2014; Bonucci et al., 2015). The self-
aggregation of maculatin 1.1, a membrane-active antimicrobial
peptide (AMP) from the Australian tree frog leads to deeper
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penetration into the membrane core and significant change
of curvature of the membrane (Bond et al., 2008). The self-
aggregation of AMPs leads to an enhanced local concentration
of AMPs around the membrane and has been used to design
multimeric AMPs (Arnusch et al., 2007; Bai et al., 2012; Shin et al.,
2013; Lakshminarayanan et al., 2014; Koh et al., 2015a).
METHODS FOR AMP DESIGN
Although research on AMP development has been highly active
in the past years, few molecules have entered into the market.
For an AMP to be used as a therapeutic agent, it needs
to possess several druggable properties: (i) high antimicrobial
activity; (ii) low toxicity to the mammalian membrane; (iii)
high proteolytic stability; (iv) low serum binding; and (v) low
cost. Most AMPs have minimum inhibitory concentration (MIC)
values<10µg/ml, while conventional antibiotics may haveMICs
in the range of 1–2 µg/ml or even sub µg/ml range, suggesting
that significant effort is still needed to design new AMPs with
higher activity. Various approaches have been employed to design
new AMPs with low MIC, high stability, and low toxicity.
These methods include the time-consuming mutation based
empirical method, statistically based bioinformatics methods,
and more sophisticated mechanism based methods such as
MD simulations and biophysical experiments. Recently, multi-
disciplinary approaches combining computational predictions,
biophysical characterizations and biological validations have
proved to be more promising (Bai et al., 2012; Koh et al., 2015a;
Lakshminarayanan et al., 2016). This section discusses various
experimental and computationalmethods that have been used for
AMP design. Clearly, if the details of the membrane interactions
were known design of an appropriate AMP would be facilitated.
Mutation Based Empirical Methods
Early attempts to design AMPs were largely carried out by trial
and error due to poor understanding of the action mechanism.
Many designed AMPs are actually based on the modifications
of existing natural AMPs. A number of approaches can be tried
to re-engineer a naturally occurring AMP, such as sequence
shuﬄing and alanine scanning. Sequence shuﬄing, in which the
positions of the amino acids in the sequence are changed can
be the simple sequence reversal or via a combinatorial library.
Since sequence shuﬄing does not change the hydrophobicity
and the net positive charges, it has been used to optimize the
antimicrobial activity of specific AMPs (Monroc et al., 2006;
Cherkasov et al., 2009). The technique of alanine scanning
mutates each residue or a group of residues to alanine and the
antimicrobial activity is monitored for improvement. Alanine
scanning has been widely used in AMP design and has proved
to be very useful in identifying residues critical for antimicrobial
activity (Grieco et al., 2011; Hänchen et al., 2013).
Statistically Based Bioinformatics Methods
AMP databases enhance computer aided AMP design (Fjell
et al., 2007; Thomas et al., 2010; Wang G. et al., 2016).
Various bioinformatics tools have been developed, including
simple statistical modeling, SARs, neural networks, and machine
learning. In general, these bioinformatics based tools need a
database with known antimicrobial activity of certain peptides
as the training set. By using different bioinformatics algorithms,
key structural, and biophysical features are extracted from the
training set and can be used to predict the antimicrobial activity
of unknown peptides, which is referred to as the test set.
For example, Mishra and Wang employed database filtering
technology to determine the key parameters of AMPs (e.g., amino
acid composition, peptide hydrophobic content, and net charge)
and subsequently used these parameters for the ab initio design
of potent AMPs againstMRSA (Mishra andWang, 2012). Besides
the AMP database, design principles can also be obtained from
other sources, such as genomes and proteomes (Li et al., 2007;
Brand et al., 2012; Kim et al., 2016).
Mechanism Based Methods
Although the bioinformatics methods are simple and fast, they
are still black boxes, as there is little information that reveals the
actionmechanisms. Amore powerful and rational method would
be to design new AMPs based on the mode of interaction with
the membrane. To this purpose, detailed understanding of the
action mechanisms of existing AMPs is required. MD simulation
is a powerful method that can give atomistic information
regarding the interactions of AMPs with bacterial membranes.
If the time scale of the simulation is long enough, membrane
disruption or pore formation can be directly observed (Wang
Y. et al., 2016). MD simulations have been previously used to
decipher the action mechanism of AMPs, and recently have been
successfully applied to the design of new AMPs and antimicrobial
peptidomimetics (Tsai et al., 2009; Tew et al., 2010a; Li et al., 2013,
2015; John Fox et al., 2016). For example, Bai et al. performed
atomistic MD simulations of a short cationic AMP B1088 and
found that the charge density plays an important role in its
interactions with bacterial membrane mimics (Bai et al., 2009).
Based on this information, they subsequently designed a covalent
peptide dimer B2088 and a tetramer B4010 which demonstrated
enhanced antimicrobial activity and proteolytic stability (Li et al.,
2013; Lakshminarayanan et al., 2014). By using coarse-grained
MD simulations, Tew et al. successfully designed a number of
synthetic mimics of AMPs with high membrane selectivity (Tew
et al., 2010a). One of their compounds brilacidin is currently
under phase II clinical trials.
NMR can also provide mechanistic details for improved AMP
design and in fact complements MD simulations. Similar to MD
simulations, NMR, particularly solid state NMR, can provide
information regarding the 3-D conformation of the peptide as
well as the mode of interactions with model lipid membranes
(Strandberg and Ulrich, 2004; Su et al., 2010). These include
identification of the biophysical properties of critical residues
that mediate the interactions with the membrane. For instance,
Saravanan et al. used NMR combined with other biophysical
experiments to design tryptophan and arginine rich decamer
peptides and potent antimicrobial activity and low toxicity of
the decamer peptide were found to arise from an optimal ratio
between the positive charges and hydrophobicity (Saravanan
et al., 2014). Later the same group used NMR to further design β-
boomerang lipo-peptides that neutralized LPS (Mohanram and
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Bhattacharjya, 2014). Jeong et al. used NMR experiments not
only to design a series of LPcin analogs with potent antimicrobial
activities, but also elucidated the 3-D structure of a peptide-
membrane complex (Jeong et al., 2016).
Principles for Practical Design of AMPs
Based on the methods discussed above, some general design
principles have been proposed which can be directly used to guide
AMP design and are briefly discussed below.
Amphiphilicity
Amphiphilicity is perhaps the most striking feature of AMPs,
including facial amphiphilicity (Vandenburg et al., 2002),
bola-amphiphilicity (Ali, 2007), radial amphiphilicity (Xiong
et al., 2015), etc., all with at least one cationic moiety
and one hydrophobic moiety. Considering the amphiphilic
nature of membranes, amphiphilic peptides are expected to
have high membrane affinity. Facially amphiphilic AMPs are
usually helical with one side being cationic and the other
side being hydrophobic. When adsorbed onto the bacterial
membrane, these AMPs locate at the membrane surface, with
the cationic face interacting with the head groups and the
hydrophobic face penetrating into the lipid tail region, resulting
in significant perturbations at the membrane-water interface. On
the other hand, bola-amphiphilic peptides are expected to adopt
transmembrane conformations, driven by hydrophobic match.
In such a case, the two cationic moieties interact with the two
head group regions, while the hydrophobic moiety interacts with
the lipid tails. When several bola-amphiphilic peptide molecules
oligomerize in the bacterial membrane, membrane pores can be
formed (Matile et al., 2011).
Peptide Crosslinking
As both the pore forming mechanism and the carpet mechanism
depend on the concentration of the peptide on the bacterial
membrane surface, various methods have been proposed to
enhance the surface concentration of AMPs. An effective way to
enhance surface concentration of AMPs is through peptide self-
aggregation, which leads to more effective membrane disruption
compared to the monomeric peptide. For example, LL-37 self-
aggregates on the bacterial membrane leading to the formation
of toroidal pores (Bonucci et al., 2015). However, if the
peptide is highly cationic, the self-aggregation is inhibited due
to electrostatic repulsion between AMP molecules. In such
a case, covalent linking can be used to generate covalent
peptide aggregates, known as multimeric peptides. As discussed
above, the covalent peptide dimer B2088 and tetramer B4010
displayed much higher antimicrobial activity than the peptide
monomeric unit comprising these peptides (Bai et al., 2012;
Lakshminarayanan et al., 2014, 2016).
Role of Arg
Most AMPs are cationic as a result of a high percentage of
basic residues, Lys or Arg. Although both carry positive charges
at neutral pH, the pKa values of Arg (12.45) and Lys (10.5)
are different, and this will affect their protonation states in the
membrane environment. Theoretical calculations found that Arg
will retain its protonation state in the lipid tail region of the
membrane, while Lys becomes deprotonated in the bilayer center
(Yoo and Cui, 2008, 2010; Gleason et al., 2013). Due to the
high pKa and multi-dentate hydrogen bonding property of Arg,
Arg-rich peptides are thought to have stronger interactions with
membranes. For example, a twin-arginine motif was found to
assist peptide translocation and polyarginine itself is an efficient
cell penetrating peptide (Chaddock et al., 1995; Bechara and
Sagan, 2013). Studies also showed that Arg can induce more
negative Gaussian curvatures than Lys due to its bidentate
hydrogen bonding with PO4 groups (Schmidt et al., 2010,
2011; Schmidt and Wong, 2013; Wu et al., 2013). Accordingly,
various Arg-rich AMPs have been designed. For example, (RW)n
peptides display excellent antimicrobial activity (Liu et al., 2007).
The side chain of Arg residue, the guanidine group was found
to greatly enhance the action of antimicrobial peptidomimetics
compared to the side chain of Lys residue (Andreev et al., 2014).
Although many studies have shown the preference of Arg over
Lys in terms of antimicrobial activity, some peptides prefer Lys
over Arg residues. For example, arginine modified polymyxin B
displayed reduced antimicrobial activity, suggesting that there
appears not to be a general rule for selective preference of Arg
and Lys by AMPs (Rabanal et al., 2015).
Peptide Truncation
Most of the classical antimicrobial peptides are fairly large and
expensive to synthesize. This has led to the design of ultra-short
peptides, with only 3–4 amino acids. The sequence of the peptidic
moiety and the length of the hydrophobic moiety appear to
determine the spectrum of antimicrobial activities. Despite their
short lengths, their modes of action involves permeation and
disintegration of the membrane organization, similar to that of
many classical AMPs (Makovitzki et al., 2006) As electrostatic
interactions with the bacterial membrane are still involved,
almost all ultrashort peptides designed and synthesized to date
contain cationic amino acids, such as arginine and lysine (Findlay
et al., 2012; Domalaon et al., 2014; Mishra et al., 2015) For
instance, KYR is an amino acid sequence of bovine hemoglobin
alpha chain, which was part of the longer amino acid sequence
that was obtained from hydrolysing the hemoglobin alpha chain.
KYR is one of the shortest AMPs known (Nasompag et al.,
2015). Most of the ultrashort peptides are conjugated with a fatty
acid tail to provide additional hydrophobicity to kill bacteria
efficiently (Makovitzki et al., 2006)
Incorporating Unnatural Amino Acids
The synthetic AMPs are not restricted to the 20 natural amino
acids. Instead, they can incorporate various unnatural amino
acids or have additional chemical modification. The direct
advantage of AMPs containing unnatural amino acids is their
high proteolytic stability. More importantly, as AMPs require a
delicate balance of cationic and hydrophobic groups, chemical
modifications enables easy fine-tuning of the hydrophobic
balance. The commonly used approach for chemicalmodification
includes use of more hydrophobic amino acids, lipid, and
aromatic modifications. For example, lipid modifications of the
above mentioned peptide dimer B2088 results in C8-B2088,
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which demonstrated enhanced antimicrobial activity (Koh et al.,
2015a). Similarly, modification of the Phe residue with an
additional benzene ring significantly enhances the antimicrobial
activity of a short peptide FRFR-NH2, while maintaining its
low toxicity to mammalian membranes (Lau et al., 2015).
Multiple modifications have been used together to achieve high
activity. LTX-109, a short synthetic AMP with both lipid and
aromatic modifications, has been in clinical trials (Saravolatz
et al., 2012b). Recently, a pharmacophore model has been
proposed for the design of short AMP mimetics with the
sequence of RXR, where X is a hydrophobic scaffold (Li et al.,
2015). Derivatives of the pharmacophore model have shown
excellent activity against resistant pathogens, low toxicity to
mammalian membranes, and extremely high stability (Koh et al.,
2015b).
Current Status: Examples of
AMPs/Peptidomimetics in Clinical Trials
In the past 30 years, continuous efforts have been made to
develop AMPs as clinically useful antimicrobials due to their
advantages over conventional antibiotics such as a rapid bacterial
killing, good selectivity toward the bacterial membrane, and a low
propensity to give rise to bacterial resistance (Bai et al., 2012).
However, to date, no designed AMP antibiotics have yet reached
the clinic. Nevertheless, as described below, a number of AMPs
and AMP derivatives are already at the pre-clinical stage and in
clinical trials.
PL-5 is an α-helical AMP with a sequence of Ac-K-W-K-S-
F-L-K-T-F-K-S-A-A-K-T-V-L-H-T-A-L-K-A-I-S-S-amide, where
Ac=N-acetyl and amide= C-terminal amide. PL-5 is developed
by ProteLight Pharmaceuticals and has recently obtained
approval from the China Food andDrug Administration (CFDA)
to enter clinical trials for skin infection in the year 2016. It is
noteworthy that PL-5 is the first AMP to enter the clinical stage
in China. PL-5 is a low toxicity and highly potent AMP against
a broad spectrum of drug-resistant bacteria. In addition, PL-
5 is able to synergize with conventional antibiotics to improve
antibacterial activity in vitro and in vivo against both Gram-
positive and Gram-negative bacteria. This may help prevent or
delay the emergence of antibiotic resistance (Feng et al., 2015).
POL7080 is a synthetic cyclic peptide derived from protegrin
I. POL7080 is active against Gram-negative bacteria and works
by inhibiting a homolog of the β-barrel protein LptD. LptD
is an outer-membrane protein widely distributed in Gram-
negative bacteria that functions in the assembly of LPS in
the outer leaflet of the outer membrane (Braun and Silhavy,
2002) LptD is involved in the outer-membrane biogenesis
of lipopolysaccharide. Significantly, POL7080 is highly active
on a broad panel of clinical isolates including multi-drug
resistant Pseudomonas with outstanding in vivo efficacy in
septicemia, lung and thigh infectionmodels (Polyphor) POL7080
is developed by Polyphor Ltd and has competed a phase I clinical
trial with its partner Roche. POL7080 has also completed a phase-
II trial in 20 patients with exacerbation of non-cystic fibrosis
bronchiectasis in 2015 (Butler et al., 2017). To date, the structure
of POL7080 has not been revealed.
DPK-060 is a cationic peptide that has recently completed
a Phase II study of topical application for atopic dermatitis.
DPK-060 is a broad spectrum cationic peptide active against
both Gram-positive and Gram-negative bacteria. Similar to other
AMPs, DPK-060 is alsomembrane targeting (Harvey et al., 2015).
DPK-060 is developed by Pergamum AB. The results from a
Phase II clinical trial of DPK-060 in outer ear infections showed
a statistically significant improvement in a 10-day cure rate
compared to placebo and that DPK-060 is safe and tolerable (Lee
et al., 2015) However, no recent reports of DPK-060 development
have been forthcoming. PergamumAB has also developed LL-37,
a human cathelicidin subunit. Human cathelicidin is synthesized
by numerous cells as an inactive precursor, hCAP18/LL-37.
It consists of a highly conserved N-terminal signal sequence,
a conserved cathelin domain, and a small antimicrobial C-
terminal domain. The small antimicrobial C-terminal domain
is known as LL-37 (Vandamme et al., 2012). The LL-37
domain is released by cleaving the proteolytic hCAP18/LL-37
precursor. This domain exhibits antimicrobial activities against
both Gram-positive and Gram-negative bacteria (Overhage
et al., 2008; Barlow et al., 2011) LL-37 has a peptide sequence
of LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRT. LL-37 is
developed for treatment of chronic leg ulcers. The clinical phase
results show that LL-37 has a significantly improved healing rate
compared to placebo (Lee et al., 2015).
Innate Defense Regulators (IDRs) are a novel class of synthetic
peptides that enhance the control of microbial infections.
IDRs do not impact the adaptive immune system and do not
interfere with chemotherapy, radiation therapy or antibiotic
treatments. SGX942 contains the active ingredient dusquetide
(also referred to as SGX-94). Dusquetide is a fully synthetic, 5-
amino acid peptide derived from Indolicidin with high aqueous
solubility and stability (Soligenix) SGX94, has broad-spectrum
activity against Gram-negative and Gram-positive bacterial
infections caused by intracellular or extracellular bacteria and
also complements the actions of standard of care antibiotics
(North et al., 2016). Since SGX-94 acts through host pathways
to provide both broad-spectrum anti-infective capability as well
as control of inflammation, IDRs are unlikely to be impacted by
resistance mechanisms. It also offers potential clinical advantages
in the fight against emerging and antibiotic resistant bacterial
infections (North et al., 2016) SGX-942 was first developed by
Inimex and is currently being pursued in a Phase-II trial by
Soligenix as treatment for oral mucositis (Butler et al., 2017).
SGX942 has previously demonstrated safety and tolerability in
a double-blind, placebo-controlled, healthy volunteer Phase I
clinical trial. SGX942 has been awarded Fast Track designation
from the FDA for the treatment of oral mucositis as a result
of radiation and/or chemotherapy treatment in head and neck
cancer patients.
There are also several AMPs that were not approved by FDA
or failed at an earlier development stage, such as Iseganan,
Omiganan, and XMP-629 and Locilex (Ahmad et al., 2012).
Dipexium acknowledged that Locilex did not meet the primary
clinical endpoint of superiority vs. placebo or “vehicle” namely
the cream without its active ingredient of pexiganan. In
order to overcome the major limitations of AMPs such as
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systemic toxicity and proteolytic instability, the development of
small-molecule-based membrane-targeting antimicrobials that
maintain the essential key characteristics of AMPs, has received
considerable attention (Lohan and Bisht, 2013). Peptidomimetics
are a new generation of small-molecule antimicrobials that
mimic the structure and antibacterial action of AMPs. Design
of peptidomimetics involves the introduction of amide bond
isosteres or peptide backbone modifications via non-natural side
chains to mimic a peptide structure or function (Niu et al., 2012;
Lohan and Bisht, 2013).
Brilacidin is a small-molecule arylamide mimic of AMPs
that shows potent antimicrobial activity against a wide range
of drug-susceptible and multidrug-resistant Gram-negative and
Gram-positive bacteria (Tew et al., 2002, 2010b; Liu et al., 2004)
Brilacidin has a planar, conformationally restrained scaffold
with four positive guanadinyl and pyridinyl substitutions and
two trufluoromethane hydrophobic substitutions (Figure 4).
Brilacidin was first developed by Polymedix Inc. and purchased
by Cellceutix corp. in September 2013 (Butler et al., 2017).
Brilacidin has completed phase IIa and phase IIb trials for the
treatment of acute S. aureus skin and skin structure infections.
Compared to daptomycin, the results show no serious adverse
effects and the efficacy is similar to daptomycin across all
brilacidin treatment groups in 215 patients Similar to other
AMPs, brilacidin is a membrane targeting antimicrobial. It causes
membrane disruption and shows efficacy in a MRSA keratitis
model when applied topically. At 0.5% solution, brilacidin shows
minimal irritation and is equally efficacious as vancomycin
(Kowalski et al., 2016) In addition to brilacidin, Cellceutix
is also developing CTIX-1278 (structure not revealed), a
defensinmimetic-compound, against the drug resistant superbug
Klebsiella pneumoniae. CTIX-1278 is efficacious in a thigh burden
study using a mouse model. The results are encouraging as
CTIX-1278 shows similar efficacy compared to carbapenem.
LTX-109 is developed by Lytix Biopharma, which focus
on topical treatment of skin infections and nasal eradication
of staphylococcus. LTX 109 is a synthetic antimicrobial
peptidomimetic, which has completed phase 2 trials for the
treatment of impetigo in the year 2014 and uncomplicated
skin and skin structure infection (uSSSI) in the year 2011
(Butler et al., 2017). LTX-109 has the chemical structure Arg-
Tbt-Arg-NH-EtPh (Figure 4). Arg provides the cationic charge
and the tertiary butyl group is important to increase the
hydrophobicity. In general, LTX-109 is active against a broad
range of bacteria including E. coli and S. aureus (Isaksson
et al., 2011a) Significantly, LTX-109 is also active against a
panel of drug-resistant Gram-positive bacteria, such as MRSA,
vancomycin-intermediate resistant, daptomycin resistant, and
linezolid-resistant strains (Saravolatz et al., 2012a) LTX-109 kills
bacteria via the membrane targeting mechanism.
Exeporfinium chloride (XF-73) is a synthetic dicationic
porphyrin derivative being developed by Destiny Pharma
(Brighton, UK) that has been evaluated in phase-I/II trials for
the prevention of post-surgical staphylococcal nasal infections
(Figure 4; Butler et al., 2017). XF-73 has completed 5 Phase
I/IIa clinical studies in Europe/US. XF-73 is a photosensitizer
that has broad-spectrum antimicrobial activities against Gram-
positive, Gram-negative and Candida albicans (Farrell et al.,
2010; Gonzales et al., 2013). XF-73 exhibits potent, non-
lytic, bactericidal activity against S. aureus. Similar to AMPs,
FIGURE 4 | Structures of AMP mimetics in clinical studies. All the three molecules contain a large hydrophobic moiety and two cationic moieties, forming a
cationic-hydrophobic-cationic motif, and mimicking the interactions of AMPs with the bacterial membrane.
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interaction of XF-73 with the cytoplasmic membrane is lethal
to S. aureus, leading to release of intracellular components and
bacterial cell death (Ooi et al., 2009). In addition, XF-73 showed
no drug resistance emergence from four common MRSA strains
tested in a multi-step (55 passage) resistance study, as a ≤4-
fold increase in MIC against the strains tested (Farrell et al.,
2011). On 05 September 2016, Destiny Pharma announced that
XF-73 can be delivered safely and is well-tolerated in a two-
stage US clinical trial using intra-nasally applied exeporfinium
chloride gels (DMID contract number HHSN27220800026C).
In addition, no drug was detected in the bloodstream (Destiny
Pharma, accessed on 12 January 2017).
Peptides have appeared in a wide range of applications in
other clinical areas (Fosgerau andHoffmann, 2015). For instance,
thymalfasin, a short peptide with 28 amino acids, has been used in
clinics for its immune regulatory function (Sjogren, 2004). With
more and more emerging strategies to design new generation
AMPs with improved efficacy, safety, and tolerability, we believe
that peptide antibiotic still offer enormous growth potential to
reach the clinic in the near future.
CHALLENGES AND FUTURE
PERSPECTIVES
Current AMP Development: Challenges
and Solutions
AMP development has been an active research area in the past
30 years, but only recently has there been a positive outlook
for commercial success. There are challenges that limit the
design of potent AMPs, such as the poor understanding of the
target-drug interaction and the lack of rational design principles.
Besides activity, issues such as toxicity, serum binding, stability,
and product cost are also practical considerations. Solutions to
overcome these limitations have been proposed and have become
hotspots of current AMP research and development. A side
benefit of AMP research is that emphasis has changed from
screening unknowns in a microbiology setting to defining the
target bringing antibiotic development closer to conventional
structure based drug development.
Toxicity of AMPs can occur at different levels, including
membrane toxicity, cellular toxicity, and systemic toxicity.
Membrane selectivity is a widely accepted parameter to
characterize in vitromembrane toxicity and is defined as the ratio
of HC50/MIC, where HC50 is the concentration needed to cause
50% hemolysis of human red blood cells. As stated earlier in this
reviewmolecular charge of bacterial membranes and membranes
of human cells differ so that AMPs with higher positive charges
show enhanced affinity for the bacterial membrane, resulting in
higher antimicrobial activity (lower MIC) and conversely less
toxicity to human cells (Zelezetsky and Tossi, 2006). Moreover,
it is also proposed that AMP hydrophobicity can affect human
membrane toxicity, a factor useful in the design of branched
lipo-peptides with minimal toxicity (Koh et al., 2015a).
Cellular/metabolic toxicity and systemic toxicity are more
difficult to predict as the underlying mechanisms are complex.
Cellular toxicity refers to single cell toxicity, which can be
measured for human cells using MTT assays, LDH release,
and ATP synthesis (Fotakis and Timbrell, 2006). Systemic
toxicity can arise from various effects such as activation of
transcription factors, binding to macromolecular receptors in
the body, alteration of metabolic pathways, and triggering
immune response, making it challenging to predict. For example,
polymyxin B, the last resort for the treatment of multi-
drug resistant Gram-negative bacteria, although safe at the
membrane level, can cause significant nephro- and neurotoxicity
(Falagas and Kasiakou, 2006). To address and predict the
issues surrounding systemic toxicity, several strategies have
been employed. Computational toxicology usesmachine learning
algorithms to predict toxic outcomes (Valerio, 2009). Another
strategy is via formulation (Carmona-Ribeiro and de Melo
Carrasco, 2014). For example, Gramicidin, a topical AMP
is effective against many Gram-positive bacteria, but has
significant hemolysis. However, incorporating gramicidin in a
dioctadecyldimethylammonium bromide (DODAB) bilayer not
only results in reduced toxicity, but also leads to broader
antimicrobial activity against both E. coli and S. aureus (Ragioto
et al., 2014).
AMPs consisting of all natural amino acids may need to
enhance their proteolytic stability. This limitation may not
be a serious problem for topical applications, but results in
significantly reduced half-life in systemic applications. Various
approaches can be used to enhance the proteolytic stability of
AMPs. The direct way is to mutate key amino acids at the
cleavage site to D amino acids or similar analogs. For example,
arginine can be replaced by D-Arg or homoarginine, while lysine
can be replaced by D-Lys or ornithine. However, the effect of
L-to-D mutation on the antimicrobial activity needs to be re-
evaluated, although in most cases the L-to-D mutation does not
alter the antimicrobial activity significantly (Hong et al., 1999;
Berthold et al., 2013; Carmona et al., 2013). In addition, chemical
modifications as discussed in Section Principles for Practical
Design of AMPs, such as incorporation of unnatural amino acids
and cross-linking can function to improve peptide stability.
Cationic AMPs tend to display high affinity for serum
proteins, decreasing the available concentration of drug; however,
at the same time this is a general issue with most antibiotics. For
example, it was shown that AMPs can interact with drug site II of
albumin via hydrophobic interactions (Sivertsen et al., 2014). In
addition, the cationic residues of most cationic AMPs make them
good substrates for the chymotrypsin family of endoproteases
(Perona and Craik, 1997). The strong protein binding property
significantly reduces the effective concentration of the AMP
available to combat bacteria (Svenson et al., 2007). Moreover,
host cells can also interfere with the activity of AMPs. Starr et al.
pointed out that interactions with host cells can lead to significant
loss of activity in vivo, in a way very similar to the effects of
serum protein binding (Starr et al., 2016). To develop AMPs with
less binding to serum proteins/host cells, detailed PK/PD studies
are required. Compared to small molecule antibiotics, AMPs
may be more expensive to produce; however, this limitation can
be overcome by the use of synthetic biology (Cameron et al.,
2014). Using genetically engineeredmicrobial fermentation, large
amounts of recombinant peptides can be produced. For example,
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a fusion protein containing the antimicrobial sequence at its C-
terminus was successfully expressed in E. Coli., and subsequent
cleavage released AMP P2 (Haught et al., 1998).
Future Perspectives
Importantly, AMPs probably represent the best option for
the treatment of multi-drug resistant infections. Considerable
effort has been expended in this area with progress and a
number of AMP/peptidomimetics are in different phases of
clinical trials. Since the MIC values for most AMPs are still
higher than many conventional antibiotics, the primary task
is to improve the antimicrobial activity, reduce the toxicity,
and improve delivery efficiency. Another promising area is
the design of membrane active peptidomimetics to mimic
the action of existing AMPs, which can be achieved by
chemical modification of existing AMPs or using unnatural
amino acids. Compared to AMPs, peptidomimetics greatly
expand the molecular space of membrane active antimicrobials
and have the advantages of high proteolytic stability and
optimizing the hydrophobicity. However, this needs to be
coupled with the more detailed understanding of the molecular
and atomistic interactions between AMPs/peptidomimetics and
the molecular complex of the Gram-negative membrane system.
Computer aided drug design, particularly the mechanism based
in silico design approach such as MD simulations has a
great potential to help overcome some of these limitations.
When combined with other methods in a multi-disciplinary
setting, translation of fundamental knowledge to practical
clinical therapeutics can be greatly accelerated. This approach
should also be activated to overcome the AMP resistant
strains such as the recently appeared colistin (also known as
polymyxin E) resistant strains (Fernández et al., 2013; Olaitan
et al., 2014; Li et al., 2015). The advantages of combining
the in silico simulations and NMR is that the approach is
adaptable to the challenge of bacteria with modified LPS
structure. If successful a new age of antibiotics could be
forthcoming with less resistance, longer clinical utility and
greater opportunities for special purpose design of antibiotics and
other antimicrobials.
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